In recent years, there have been major advances in the treatment of patients with gynecologic malignancies. Perhaps the biggest advances have been in the area of ovarian cancer. Gynecologic Oncology focuses primarily upon this malignancy.
This volume discusses cytoreductive surgery; screening for ovarian cancer; chemotherapy; new chemotherapeutic drugs; the controversy regarding the role of high-dose chemotherapy in gynecologic cancers; the hereditary basis for gynecologic malignancies; molecular genetics; molecular biology and new biologic therapies.
Other topics covered are the treatment of all stages of cervical cancer, including radiotherapy. In addition, a chapter on advances in the pathology of gynecologic cancers is included.
The advances made in the treatment of gynecologic malignancies are due, in part, to the clinical studies performed by many of the contributors to this volume. Clinical advances have been the result of multidisciplinary approaches which involve molecular biologists, pathologists, radiation therapists, surgeons and chemotherapists. Future advances will continue to rely upon collaborative interaction among these different disciplines.
Comentarios de la gente - Escribir un comentario
No encontramos ningún comentario en los lugares habituales.
HAMILTON STEVEN W JOHNSON
Advances in the Treatment of Cervical Cancer
Advances in Cytoreductive Surgery of Gynecologic Cancers
Chemotherapy of Ovarian Cancer
HighDose Chemotherapy in Gynecologic Malignancies
Otras ediciones - Ver todas
activity adenocarcinoma analysis antibody antigen associated BRCA1 breast cancer Cancer Res cell cervical cancer cervical carcinoma chemotherapy chromosome cisplatin Clin Oncol clinical combination compared complete correlation cytoreductive demonstrated detected developed disease dose early effect endometrial epithelial ovarian et al evaluation expression gene genetic grade growth Gynecol Oncol gynecologic hereditary human identified ifosfamide important improved increased invasive laparoscopic levels lymph node Lynch malignant moles mutations neoplasms normal observed Obstet Gynecol occur Oncology ovarian cancer ovarian carcinoma ovary P-glycoprotein paclitaxel Pathol patients pelvic phase ploidy positive potential primary prognostic factors protein radiation radiation therapy radical radiotherapy randomized received recent receptor recurrent relative reported residual response risk screening serum CA 125 showed significant specific squamous stage suggest surgery surgical survival syndrome testing therapy tissue treated treatment trial tumor women